Search
Healthcare & Pharma

Pharma, Biotech Ratings Aided by Demand, but Costs in Focus

Learn More

01Insights

None available at this time

Digital Report

Credit Journal: Healthcare

This edition of Fitch Ratings’ Credit Journal takes a deep dive into the healthcare and pharma industry through global, cross-sector healthcare commentary and analysis.

Learn More

02Reports

The Checkup: High-Yield Healthcare Handbook

The Checkup: High-Yield Healthcare Handbook, is a compendium of the business profiles and capital structures of 22 of the largest issuers of high-yield debt in the U.S. healthcare industry.

CARES Act Grants Will Defray Cost of US Hospital Business Disruption

The Coronavirus Aid, Relief and Economic Security (CARES) Act grants will partially offset the effects of pandemic-related business disruption on hospital companies’ revenue and EBITDA in second-quarter 2020.

Testing to Lessen Virus’ Effect on US Device, Diagnostics Results

Testing, cost cutting and debt reduction will limit the coronavirus pandemic’s effect on US medical device and diagnostics company earnings and credit profiles.

03Corporates Navigator

Navigator Interactive

Ratings Navigator is a visual overview of the key quantitative and qualitative factors Fitch analyzes to arrive at an entity’s credit rating. Power your rating simulations for Corporates with the new Navigator Interactive—a graphical web-based tool, using the same observations underlying Fitch’s own Navigator snapshots. Fitch Ratings Corporates Credit Research subscribers can access it here.

Request a Demo

04Webinars

Our Approach

Criteria

Criteria explain our forward-looking ratings approach. Criteria reports identify rating drivers and assumptions, and highlight the scope and limitations of our analysis.

Learn More

05Videos

Nearshoring is a Multi-Year Tailwind for Mexican Corporate Credits

Nearshoring is a Multi-Year Tailwind for Mexican Corporate Credits

Credit Outlook 2023 - U.S. Life Plan Communities’ 2023 Sector Outlook Revised to ‘Deteriorating’

Credit Outlook 2023 - Deteriorating Outlooks on Half of APAC Corporate Sectors Amid Weaker Macro Backdrop

Australian Corporate Issuer Expectations Dampened by Cost and Labour Challenges

US Biomanufacturing Plan Poses Minor Risks to Chinese Pharma CDMOs

Financial Leverage to Improve for Japan’s Top-100 Corporates

Cyber Risk Mitigation Adds to Cost Pressure for Not-for-Profit Hospitals

2022 Mid-Year Outlook - Global Corporates are Adequately Equipped to Weather Risks in 2022

APAC ‘BBB-’ and ‘BBB’ Corporates: Stagflation Downgrade Risk

Impact of Adverse Economic Scenario on EMEA Corporates

Global Pharma and Biotech Pivots Towards R&D Productivity

2022 Credit Outlook - Innovation Drives Growth in Global Big Pharma & Biotech

2022 Credit Outlook - U.S. Healthcare and Pharma Outlook Neutral for 2022

2022 Credit Outlook - Rising Labor Expenses Cloud U.S. NFP Hospitals

2022 Credit Outlook - Fitch Expects Operating Environment for LPCs to Remain Unchanged in 2022

US Healthcare System to Expand, Adapt to Long-Term COVID-19 Fallout

Relentless Cyber Attacks to Pressure NFP Hospitals’ Operations

India’s Second Wave Manageable for Most Companies; Swift Rebound Expected in Auto Demand

A Higher US Corporate Tax Rate Is Not a Key Credit Risk Driver

Pandemic Fallout to Delay US Drug Price Reform, Biosimilars Uptake

LATAM Spotlight Series: New Cross-Border Issuers Span Multiple Sectors and Countries

Fitch Ratings 2021 Outlook - US Municipal Sectors

U.S. Healthcare and Pharma Outlook Stable for 2021

APAC Corps to Recover in 2021, but Cash Flow Weaker than 2019

US Pharma COVID-19 Vaccine to Benefit Revenue More than Margins

NFP Hospitals Brace for Another COVID-19 Wave

Telehealth Provides US Healthcare Temporary Revenue Stop Gap

The Recovery Curves for Major Healthcare Sectors - Providers, Pharmaceuticals, Medical Products

US Healthcare is Resilient but Not Immune to Effects of Coronavirus

More Videos

06Sector Analysts

Debora Jalles
Corporate Ratings - LATAM
Director
+1 312 606 2338 |

Pablo Mazzini
Corporate Ratings - EMEA
Senior Director
+44 20 3530 1021 |

Vicky Melbourne
Corporate Ratings - APAC
Managing Director
+61 2 8256 0325 |

Britton Costa
Head of U.S. Healthcare & Pharma
Senior Director
(1) 212 908 0524 |

07Business Contacts

Jill Zelter
Global Head of Corporates and Structured Credit
Managing Director
+1 212 908 0774 |

Kathleen Holtzman
Head of LATAM Sovereigns & Corporates, BRM
Managing Director
+1 212 908 9103 |

Sing Chan Ng
Co-Head of APAC, BRM
Managing Director
+65 6796 7210 |

Matthew De Mendonca
BRM Corporates - North America
Managing Director
+1 646 582 4707 |

Sean Costello
BRM Corporates - EMEA
Managing Director
+44 20 3530 1883 |

Aymeric Poizot
Global Head of
Investor Development
+33 1 44 29 92 76 |